Piperacillin/tazobactam or ampicillin and gentamicin for empirical treatment of community acquired infection: A randomised clinical trial (PAGER)

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526131-20-00

Enrollment

2162

Registered

2026-08-25

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urosepsis, Infection of unknown origin, Pyelonephritis, Cystitis, Urinary tract infection, Pneumonia, Sepsis

Brief summary

Proportion dead from all causes within 30 days of randomization, Acute kidney injury defined as KDIGO stage C1 or above within 30 days of randomization

Interventions

DRUGGENTAMICIN

DRUGPIPERACILLIN AND BETA-LACTAMASE INHIBITOR

DRUGAMPICILLIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion dead from all causes within 30 days of randomization, Acute kidney injury defined as KDIGO stage C1 or above within 30 days of randomization	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 26, 2026